TY - JOUR
T1 - Folic acid functionalized surface highlights 5-methylcytosine-genomic content within circulating tumor cells
AU - Malara, Natalia
AU - Coluccio, Maria Laura
AU - Limongi, Tania
AU - Asande, Monica
AU - Trunzo, Valentina
AU - Cojoc, Gheorghe
AU - Raso, Cinzia
AU - Candeloro, Patrizio
AU - Perozziello, Gerardo
AU - Raimondo, Raffaella
AU - De Vitis, Stefania
AU - Roveda, Laura
AU - Renne, Maria
AU - Prati, Ubaldo
AU - Mollace, Vincenzo
AU - Di Fabrizio, Enzo
PY - 2014/11/12
Y1 - 2014/11/12
N2 - Although the detection of methylated cell free DNA represents one of the most promising approaches for relapse risk assessment in cancer patients, the low concentration of cell-free circulating DNA constitutes the biggest obstacle in the development of DNA methylation-based biomarkers from blood. This paper describes a method for the measurement of genomic methylation content directly on circulating tumor cells (CTC), which could be used to deceive the aforementioned problem. Since CTC are disease related blood-based biomarkers, they result essential to monitor tumor's stadiation, therapy, and early relapsing lesions. Within surface's bio-functionalization and cell's isolation procedure standardization, the presented approach reveals a singular ability to detect high 5-methylcytosine CTC-subset content in the whole CTC compound, by choosing folic acid (FA) as transducer molecule. Sensitivity and specificity, calculated for FA functionalized surface (FA-surface), result respectively on about 83% and 60%. FA-surface, allowing the detection and characterization of early metastatic dissemination, provides a unique advance in the comprehension of tumors progression and dissemination confirming the presence of CTC and its association with high risk of relapse. This functionalized surface identifying and quantifying high 5-methylcytosine CTC-subset content into the patient's blood lead significant progress in cancer risk assessment, also providing a novel therapeutic strategy.
AB - Although the detection of methylated cell free DNA represents one of the most promising approaches for relapse risk assessment in cancer patients, the low concentration of cell-free circulating DNA constitutes the biggest obstacle in the development of DNA methylation-based biomarkers from blood. This paper describes a method for the measurement of genomic methylation content directly on circulating tumor cells (CTC), which could be used to deceive the aforementioned problem. Since CTC are disease related blood-based biomarkers, they result essential to monitor tumor's stadiation, therapy, and early relapsing lesions. Within surface's bio-functionalization and cell's isolation procedure standardization, the presented approach reveals a singular ability to detect high 5-methylcytosine CTC-subset content in the whole CTC compound, by choosing folic acid (FA) as transducer molecule. Sensitivity and specificity, calculated for FA functionalized surface (FA-surface), result respectively on about 83% and 60%. FA-surface, allowing the detection and characterization of early metastatic dissemination, provides a unique advance in the comprehension of tumors progression and dissemination confirming the presence of CTC and its association with high risk of relapse. This functionalized surface identifying and quantifying high 5-methylcytosine CTC-subset content into the patient's blood lead significant progress in cancer risk assessment, also providing a novel therapeutic strategy.
KW - folic acid
KW - folic acid receptors
KW - functionalized surfaces
KW - hyper-methylated circulating tumor cells
UR - http://www.scopus.com/inward/record.url?scp=84928940938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928940938&partnerID=8YFLogxK
U2 - 10.1002/smll.201400498
DO - 10.1002/smll.201400498
M3 - Article
C2 - 25044603
AN - SCOPUS:84928940938
VL - 10
SP - 4324
EP - 4331
JO - Small
JF - Small
SN - 1613-6810
IS - 21
ER -